Search CDIX
Cardiff Lexington Corp
OTC · CIK 811222
Last close0.1
Daily change-0.00 (-0.00%)
10 Years gain-100.00%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CDIX · STANDARD
SIC 8011 · Services-Offices & Clinics of Doctors of Medicine · Fiscal year end 1231
Fundamental
25.3Momentum
58.5Acceleration
56.4Confidence
79.0Annual Revenue16
Quarterly Revenue49
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth13.1 / 25
Quality6.8 / 25
Capital Efficiency0.3 / 20
Balance Sheet2.2 / 15
Shareholder Economics1.7 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 7.0074 percentage points.
Operating leverageOperating margin improved by 1.7006 percentage points.
ROIC expansionROIC improved by 0.6263 percentage points.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
Heavy share dilution · HIGHDiluted share count increased 198.9679%.
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
Key Metrics
Revenue Growth TTM26.84%OK
Revenue CAGR 3Y2.56%OK
Gross Margin59.68%OK
Operating Margin1.93%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC0.84%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y198.97%OK
SBC / Revenue11.44%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $11.54M | $7.21M | $1.10M | n/a | n/a | 62.47% | 9.54% | n/a | 6.57% | 8.5M |
| 2025 FY Dec 31, 2024 | $8.27M | $4.43M | -$193,504.00 | n/a | n/a | 53.55% | -2.34% | n/a | -2.38% | 3.82M |
| 2024 FY Dec 31, 2023 | $11.85M | $8.29M | $5.20M | n/a | n/a | 69.96% | 43.83% | n/a | 2,436.09% | 15,001 |
| 2023 FY Dec 31, 2022 | $10.69M | $6.63M | $3.91M | -$1.15M | n/a | 62.03% | 36.54% | n/a | n/a | 5,822 |
| 2022 FY Dec 31, 2021 | $9.88M | $6.11M | $1.66M | n/a | n/a | 61.85% | 16.82% | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $10.23M | sum latest 4 fiscal quarters Revenue | OK | 0001683168-26-006232, 0001683168-25-008221 |
| Revenue Growth TTM | 26.84% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001683168-26-006232, 0001683168-25-008221 |
| Revenue CAGR 3Y | 2.56% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-001639 |
| Revenue CAGR 5Y | 27.28% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001683168-26-001639 |
| Gross Profit CAGR 3Y | 2.8% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001683168-26-001639 |
| Operating Income Growth | 978.35% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001683168-26-006232, 0001683168-25-008221 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 59.68% | Gross Profit / Revenue | OK | 0001683168-26-006232, 0001683168-25-008221 |
| Operating Margin | 1.93% | Operating Income / Revenue | OK | 0001683168-26-006232, 0001683168-25-008221 |
| ROIC | 0.84% | NOPAT / Average Invested Capital | OK | 0001683168-26-006232, 0001683168-25-008221 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001683168-26-006232 |
| Current Ratio | 0.91x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.01x | (Cash + Short-term Investments) / Total Debt | OK | 0001683168-26-006232 |
| SBC / Revenue | 11.44% | SBC / Revenue | OK | 0001683168-26-006232, 0001683168-25-008221 |